A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Prostate Cancer Metastatic
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 164 (final count)
- Started
- Sep 2, 2021
- Main results expected
- May 25, 2027
- Fully finished
- May 25, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of treatment
Measured over: Up to 28 days
Part C: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of treatment
Measured over: Up to 28 Days
Parts A and C: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over: From first dose through approximately 30 days after last dose
Parts A and C: Incidence of laboratory abnormalities
Measured over: From first dose through approximately 30 days after last dose
Part B: Prostate-Specific Antigen 30% Response Rate (PSA30)
Measured over: 12 Weeks
Part B: Prostate-Specific Antigen 50% Response Rate (PSA50)
Measured over: 12 Weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05067140 · record last updated 2026-08-18 · checked 2026-11-09 15:47 UTC